ASND – ascendis pharma a/s - american depositary shares (US:NASDAQ)

News

Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
Ascendis Pharma (ASND) Revenue Nearly Doubles to €720M in 2025 Fueled by Core Product Growth [Yahoo! Finance]
The Boston Globe to Host Rare Disease Summit
Ascendis Pharma A/S (NASDAQ:ASND) was given a new $325.00 price target on by analysts at Stifel Nicolaus.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com